Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma-Reference-Cited by-同舟云学术

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma

Published:2018-03-30 Issue:4 Volume:19 Page:1041
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Minnema-Luiting Jorien,Vroman Heleen,Aerts Joachim,Cornelissen Robin

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/19/4/1041/pdf

Reference56 articles.

1. Malignant mesothelioma: Facts, Myths, and Hypotheses

2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

3. Pathology of malignant mesothelioma

4. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

5. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy;2024-08-09

2. Development in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment;Cancer Biotherapy and Radiopharmaceuticals;2024-08-02

3. Leucine rich α2 glycoprotein 1 derived from malignant pleural mesothelioma cells facilitates macrophage M2 phenotypes;Experimental Lung Research;2024-07-21

4. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment;OncoImmunology;2024-07-10

5. Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models;Breast Cancer Research;2024-06-25